Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 53 The 9% GLP-1 share of the global diabetes care market is increasing, opportunities for further penetration remain VictozaⓇ sales and GLP-1 value market share of total diabetes care market Global GLP-1 market GLP-1 value in bDKK Share of total DKK GLP-1 share of diabetes care market diabetes care market billion 50 10% 12 11% CAGR value¹: 37.0% 40 10 8% 8 00 320 30 6% VictozaⓇ 6 20 10 4% 4 9% Exenatide 2% 2 4% 3% 1% Aug 2011 Other GLP-1 Aug 2016 0% 0 USA Europe Pacific Region China IO 1 CAGR for 5-year period Source: IMS Monthly MAT August, 2016 value figures (DKK) changing diabetes® Source: Novo Nordisk reported sales for first nine months of 2016 and IMS August, 2016 data novo nordisk

View entire presentation